Sugi Predict

Sugi Predict / Targets / PDK2

PDK2

[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial · Q15119 · PDK2 on Sugi Atlas →

183,603 patent compounds predicted against PDK2, 50,920 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL95711 SCHEMBL95711 0.56 19/20
SCHEMBL29114 SCHEMBL29114 0.58 18/20
SCHEMBL134285 SCHEMBL134285 0.58 18/20
SCHEMBL134286 SCHEMBL134286 0.58 18/20
SCHEMBL96056 SCHEMBL96056 0.51 18/20
SCHEMBL236472 SCHEMBL236472 0.63 13/20
Bromomethane Bromomethane (SCHEMBL208930) 0.41 13/20
SCHEMBL290998 SCHEMBL290998 0.55 12/20
SCHEMBL194556 SCHEMBL194556 0.54 12/20
SCHEMBL124841 SCHEMBL124841 0.50 11/20
SCHEMBL68561 SCHEMBL68561 0.55 10/20
SCHEMBL66735 SCHEMBL66735 0.46 9/20
Bromomethane Bromomethane (SCHEMBL208217) 0.42 8/20
SCHEMBL279070 SCHEMBL279070 0.59 7/20
SCHEMBL279228 SCHEMBL279228 0.58 7/20
SCHEMBL279367 SCHEMBL279367 0.56 7/20
SCHEMBL169589 SCHEMBL169589 0.51 7/20
SCHEMBL217779 SCHEMBL217779 0.38 7/20
SCHEMBL278203 SCHEMBL278203 0.37 7/20
SCHEMBL40434 SCHEMBL40434 0.36 7/20

Clinical trials — most relevant to PDK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients PHASE4UNKNOWN
Glutamate for Metabolic Intervention in Coronary Surgery PHASE3COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI) PHASE2RECRUITING
Thiamine as an Adjunctive Therapy in Cardiac Surgery PHASE2COMPLETED
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer PHASE2SUSPENDED
Bempedoic Acid Therapy for Polycystic Kidney Disease PHASE2NOT_YET_RECRUITING
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma PHASE2UNKNOWN
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder PHASE2WITHDRAWN
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients PHASE2UNKNOWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours PHASE1COMPLETED
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate EARLY_PHASE1ENROLLING_BY_INVITATION
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Alternative Substrates in the Critically Ill Subject nanCOMPLETED
Acute Effect of Fructose on Lipid Metabolism and Gender Differences nanCOMPLETED
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies nanRECRUITING
Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet nanCOMPLETED
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment nanUNKNOWN
Natural History Study of Pyruvate Dehydrogenase Deficiency nanUNKNOWN
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Effect of Acute Fructose Load in Human nanCOMPLETED
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy nanCOMPLETED
McArdle Disease Treatment by Ketogenic Diet nanCOMPLETED
The Impact of Mitochondrial Dysfunction on Human Bone Cell Metabolism and Remodelling nanACTIVE_NOT_RECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Hepatic Substrate Flux Rates in Type 2 Diabetes nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PDK2 binder may also engage these)

ProteinNameSimilarity
Q9JK42 — 1.000 Q9JK42 →
PDK3 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial 1.000 landscape →
Q64536 — 1.000 Q64536 →
O70571 — 1.000 O70571 →
Q1KMR4 — 0.998 Q1KMR4 →
P91622 — 0.998 P91622 →
Q2KJG8 — 0.997 Q2KJG8 →
Q9P6P9 — 0.994 Q9P6P9 →
O88345 — 0.994 O88345 →
Q02332 — 0.993 Q02332 →
O02623 — 0.992 O02623 →
PDK4 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial 0.992 landscape →
O54937 — 0.992 O54937 →
BCKDK Branched-chain alpha-ketoacid dehydrogenase kinase 0.992 landscape →
O55028 — 0.991 O55028 →
P40530 — 0.991 P40530 →
Q63065 — 0.991 Q63065 →
Q8BFP9 — 0.990 Q8BFP9 →
Q00972 — 0.990 Q00972 →
PDK1 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial 0.990 landscape →
Q922H2 — 0.990 Q922H2 →
B6JWC1 — 0.987 B6JWC1 →
P27515 — 0.987 P27515 →
Q09116 — 0.986 Q09116 →
Q9M2Q4 — 0.986 Q9M2Q4 →
P56523 — 0.986 P56523 →
Q8S6N5 — 0.985 Q8S6N5 →
Q08DA5 — 0.985 Q08DA5 →
Q8WPP2 — 0.985 Q8WPP2 →
SEPTIN6 Septin-6 0.985 landscape →